



## **Abiraterone (acetate)**

**Catalog No: tcsc0544** 

且	Available Sizes
Size:	10mg
Size:	50mg
Size:	100mg
Size:	200mg
Size:	500mg
Size:	1g
Size:	2g
Size:	5g
	Specifications
CAS N 15422	<b>No:</b> 19-18-2
Form	
<b>Pathy</b> Metab	<b>vay:</b> olic Enzyme/Protease
<b>Targe</b> Cytocl	et: hrome P450
Purity	y / Grade:
Solub	.*11*2





DMSO: 13.3 mg/mL (33.97 mM; Need ultrasonic and warming)

## **Alternative Names:**

CB7630

## **Observed Molecular Weight:**

391.55

## **Product Description**

Abiraterone acetate is an oral, potent, selective, and irreversible inhibitor of CYP17.

IC50 & Target: CYP17<sup>[1]</sup>

In Vitro: Abiraterone (Abi) acetate is an ester prodrug of the anticancer agent Abiraterone, which shows IC<sub>50</sub> values of 15 nM and 2.5 nM for the 17,20-lyase and 17 $\alpha$ -hydroxylase (CYP17 is a bifunctional enzyme with both 17 $\alpha$ -hydroxylase and 17,20-lyase activity). Abiraterone inhibits human 17,20-lyase and 17 $\alpha$ -hydroxylase with IC<sub>50</sub> of 27 and 30 nM respectively<sup>[1]</sup>.

Significant inhibition of proliferation of the AR-positive prostate cancer cell lines LNCaP and VCaP with doses of Abiraterone  $\geq 5 \mu M$  is confirmed<sup>[2]</sup>. Abiraterone inhibits recombinant human 3 $\beta$ HSD1 and 3 $\beta$ HSD2 activity with competitive K<sub>i</sub> values of 2.1 and 8.8  $\mu$ M. 10  $\mu$ M Abiraterone is sufficient to completely block synthesis of 5 $\alpha$ -dione and DHT in both cell lines. Treatment with Abiraterone significantly inhibited CRPC progression in the robustly growing subset, effectively putting a ceiling on tumor growth over 4 weeks of treatment (P[3].

In Vivo: Abiraterone (Abi) acetate prolongs survival in castration-resistant prostate cancer (CRPC). [ $^3$ H]-dehydroepiandrosterone (DHEA) depletion and  $\Delta^4$ -androstenedione (AD) accumulation are inhibited by Abiraterone in LNCaP, with an IC $_{50}$ [3].

All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!